Skip to main content
. 2022 Sep 14;4(3):65–74. doi: 10.1007/s44228-022-00015-5

Fig. 2.

Fig. 2

Impact of ibrutinib on OS in patients with CLL/SLL (A) and patients with MCL (B). CI confidence interval; CLL chronic lymphocytic leukemia; MCL mantle cell lymphoma; mo month, NE not estimable; OS overall survival; SLL small lymphocytic lymphoma